Charles Schwab’s Cymabay Therapeutics CBAY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-853,475
| Closed | -$20.2M | – | 3539 |
|
|
2023
Q4 | $20.2M | Buy |
853,475
+54,920
| +7% | +$978K | 0.01% | 1593 |
|
|
2023
Q3 | $11.9M | Buy |
798,555
+533,821
| +202% | +$7.08M | ﹤0.01% | 1824 |
|
|
2023
Q2 | $2.9M | Buy |
264,734
+226,254
| +588% | +$2.11M | ﹤0.01% | 2438 |
|
|
2023
Q1 | $336K | Buy |
38,480
+3,914
| +11% | +$31.3K | ﹤0.01% | 3060 |
|
|
2022
Q4 | $217K | Hold |
34,566
| – | – | ﹤0.01% | 3171 |
|
|
2022
Q3 | $121K | Sell |
34,566
-14,046
| -29% | -$50.5K | ﹤0.01% | 3209 |
|
|
2022
Q2 | $144K | Sell |
48,612
-190,603
| -80% | -$455K | ﹤0.01% | 3263 |
|
|
2022
Q1 | $744K | Buy |
239,215
+59,256
| +33% | +$187K | ﹤0.01% | 2968 |
|
|
2021
Q4 | $609K | Buy |
179,959
+6,000
| +3% | +$22.8K | ﹤0.01% | 3089 |
|
|
2021
Q3 | $635K | Sell |
173,959
-357,375
| -67% | -$1.41M | ﹤0.01% | 3061 |
|
|
2021
Q2 | $2.32M | Sell |
531,334
-7,780
| -1% | -$34.5K | ﹤0.01% | 2665 |
|
|
2021
Q1 | $2.45M | Buy |
539,114
+19,421
| +4% | +$105K | ﹤0.01% | 2603 |
|
|
2020
Q4 | $2.98M | Sell |
519,693
-725
| -0.1% | -$5.49K | ﹤0.01% | 2461 |
|
|
2020
Q3 | $3.77M | Buy |
520,418
+84,488
| +19% | +$452K | ﹤0.01% | 2221 |
|
|
2020
Q2 | $1.52M | Buy |
435,930
+60,665
| +16% | +$175K | ﹤0.01% | 2508 |
|
|
2020
Q1 | $556K | Buy |
375,265
+5,561
| +2% | +$9.34K | ﹤0.01% | 2677 |
|
|
2019
Q4 | $725K | Sell |
369,704
-21,394
| -5% | -$80.4K | ﹤0.01% | 2699 |
|
|
2019
Q3 | $2M | Sell |
391,098
-2,025
| -0.5% | -$12.3K | ﹤0.01% | 2377 |
|
|
2019
Q2 | $2.81M | Buy |
393,123
+28,205
| +8% | +$319K | ﹤0.01% | 2242 |
|
|
2019
Q1 | $4.85M | Buy |
364,918
+41,319
| +13% | +$439K | ﹤0.01% | 1991 |
|
|
2018
Q4 | $2.55M | Sell |
323,599
-2,052
| -0.6% | -$19.5K | ﹤0.01% | 2238 |
|
|
2018
Q3 | $3.61M | Buy |
325,651
+195,486
| +150% | +$2.43M | ﹤0.01% | 2213 |
|
|
2018
Q2 | $1.75M | Buy |
130,165
+109,800
| +539% | +$1.37M | ﹤0.01% | 2417 |
|
|
2018
Q1 | $265K | Buy |
20,365
+7,900
| +63% | +$98.2K | ﹤0.01% | 2912 |
|
|
2017
Q4 | $115K | Buy |
+12,465
| New | +$107K | ﹤0.01% | 3025 |
|
Other funds holding CBAY
Charles Schwab's CBAY Position: Q1 2024 in Review
Charles Schwab sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 853,475 shares — an estimated $20.2M sold.
Charles Schwab first reported a position in CBAY in Q4 2017 and held it in 25 quarters. The position peaked at $20.2M in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.
- Charles Schwab reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
- Charles Schwab sold 853,475 Cymabay Therapeutics shares in Q1 2024, an estimated $20.2M.
- Charles Schwab first reported a position in Cymabay Therapeutics in Q4 2017 and held it in 25 quarters.
- Charles Schwab's Cymabay Therapeutics position peaked at $20.2M in Q4 2023.
- 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.
Based on Charles Schwab's 13F filing for Q1 2024, filed 9 May 2024.